Danielle Huntsman, MS, CNS, LDN
The Hamilton Anxiety Rating Scale
Given that nearly everything about the science and clinical application of medicine has changed in the last sixty years, it is rare to find a tool that is valid, relevant, and still used today that was first created during the Eisenhower administration and before the invention of the laser. In 1959, Max Hamilton, MD developed and published the Hamilton Anxiety Scale, affectionately referred to as HAM-A.1
Imagine a world of psychiatric and psychological research without psychometrics. Dr. Hamilton was a pioneer in this area and without his contributions that world would have a much different landscape. An unconventional thinker, he studied personality types in relation to organic states early in his career.2 He encountered a number of professional obstacles along the way and his innovations rarely met with enthusiasm.2 The HAM-A was the first rating scale to be published and is available in the public domain (meaning anyone can download and use it). It is a 14-domain practitioner observation-based assessment has been shown and continues to serve as a useful tool within both a clinical and research setting. After several decades of minimal use, a significant resurgence of use of the HAM-A over the last twenty years provides over 900 references in total using a very gross bibliometric method.3
What could be responsible for the renewed interest? In 1993, a computer-administered Hamilton Anxiety Scale was developed to use in more extensive research studies as an alternative to the clinician interview version. It was shown to be almost as effective as the original practitioner-delivered version.4 The following year, Bruss and colleagues released a Hamilton Anxiety Rating Scale Interview Guide (HARS-IG). The purpose was to provide clinicians with a standardized interview format, allowing for group interviews and a reliable retest assessment tool.5 The simple, one-page observation questionnaire includes fourteen different domains, which consist of distinctive phrases and feeling associated with each domain. Inasmuch, it provides an indexed score which can be tracked serially across visits and compared to others indicating good intrasubject and intersubject reliability. These domains can be easily discussed with the patient and allow a natural conversation between practitioner and patient which is not necessarily a hallmark of similar tools.
Despite the purpose and even the name of the scale, most clinicians may be surprised by some of the areas of the interview that may, at first glance, not be directly related to its function. Yet, further evaluation supports its use.
During the visit, a practitioner should take note of the patient's behavior at the time of the appointment. For example, was she moving around a lot in the chair or did they have a hard time keeping eye contact? Clinically, this short observation-based assessment does not evaluate or go into detail about every potential sign and symptom, therefore creating some limitations. However, the elegance of this easily administrated assessment is that one domain typically will not skew results unless the results border between significant and insignificant clinical findings.
HAM-A can be used as an initial screening tool as well as a method of evaluation during active treatment in adults, children, and adolescents. It can be used by any clinician comfortable using it. Alternatively, it can be used as a reference or surrogate such that a clinician may not necessarily use the tool actively, but may make use of the results found in research that used the tool.
This is not a question that the patient completes prior or during a visit. The assessment should not be visible to the patient as this can skew results. The total administration time ranges from 10-15 minutes.
Practitioners should not be surprised if the index yields higher results than the general population or even the typical patient seen by the practice as the decision to use the assessment is a potential confounder. Confirmation bias exists in this context but does not deter from the validity of the tool for the individual patient.
The total score ranges from 0-56, with each of the 14 items being scored on a severity scale of 0 to 4. Low scores indicate greater function. A score of 25 or higher, likely calls for a psychiatric referral. Patients with scores between 18 and 24 can likely be managed by a non-specialist or an over-the-counter approach. If the score is 17 or less self-care exclusively is often recommended.
The Hamilton Anxiety Rating Scale has withstood the test of time and is respected by researchers and clinicians alike. The life of the man behind the scale is a reminder to “prevail in the face of prejudice, rejection, and defeat”.2
1. Hamilton M. Br J Med Psychol. 1959; 32:50–5.
2. Ozarin, L. Hamilton: The Man Behind the Scale. Psych News. 2002. Retrieved from https://psychnews.psychiatryonline.org/doi/full/10.1176/pn.37.20.0043a.
3. Alexandru Dan Corlan. Medline trend: automated yearly statistics of PubMed results for any query, 2004. Retrieved from http://dan.corlan.net/medline-trend.html. Accessed on 2018-02-26.
4. Kobak K et al. Psychol Assess. 1993. 5(4), 487-92. doi: 10.1037/1040-3522.214.171.1247.
5. Bruss G et al. Psychiatry Res. 1994 Aug;53(2):191-202.
V Clear EPs 7630® Cherry
V Clear EPs 7630® is an upper respiratory treatment containing a proprietary, homeopathic preparation of Pelargonium sidoides extract which addresses the underlying cause of symptoms to help speed recovery, and shorten the duration of upper respiratory irritations.
V Clear EPs 7630® Original
V Clear EPs 7630™ is an upper respiratory treatment containing a proprietary, homeopathic preparation of Pelargonium sidoides extract which addresses the underlying cause of symptoms to help speed recovery, and shorten the duration of upper respiratory irritations.
Probiotic Pearls™ are a blend of active cultures including Lactobacillus and Bifidobacterium for healthy gastrointestinal and immune function in an easy to swallow capsule.*
Esberitox™ contains immune-supporting combination of Echinacea, baptisia, and thuja.* The subject of numerous clinical trials and studies, Esberitox is among the most trusted and recommended Echinacea products available.